- Tabernero, J., Shen, L., Elimova, E., Ku, G., Liu, T. S., Shitara, K., . . . Ajani, J. (2022). HERIZON-GEA-01: Zanidatamab plus chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncology. https://doi.org/10.2217/fon-2022-0595 (En premsa)
Zanidatamab plus chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
on 17 d'octubre de 2022
with No hi ha comentaris
Deixa un comentari